An Exploratory Study of the Immunological Effects of Vemurafenib and Cobimetinib, Administered Alone and in Combination, in Subjects With Advanced BRAF V600E/K Mutant Melanoma

Trial Profile

An Exploratory Study of the Immunological Effects of Vemurafenib and Cobimetinib, Administered Alone and in Combination, in Subjects With Advanced BRAF V600E/K Mutant Melanoma

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 14 Nov 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2016.
    • 14 Nov 2016 Planned initiation date changed from 1 Apr 2015 to 1 Aug 2015.
    • 14 Nov 2016 Status changed from recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top